PGEN
$4.59
Precigen
($.08)
(1.71%)
PGEN
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.14)
Revenue:  $24.47 Mil
Monday
Nov 8
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PGEN reports earnings?
Beat
Meet
Miss

Where is PGEN's stock price going from here?
Up
Flat
Down
Stock chart of PGEN
Analysts
Summary of analysts' recommendations for PGEN
Score
Grade
Pivots
Resistance
$4.90
$4.80
$4.69

$4.59

Support
$4.48
$4.38
$4.27
Tweet
Growth
Description
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.